Your AI-Trained Oncology Knowledge Connection!
Durvalumab added to etoposide and platinum-based chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer delays development of new lesions and improves patient-reported outcomes compared with etoposide and platinum-based therapy alone.
Patients with ROS1-positive and NTRK-positive non–small cell lung cancer had frequent and durable responses, which appeared to deepen over time in some cases, with the multikinase inhibitor entrectinib.
The FDA has approved a labeling supplement for neratinib for the extended adjuvant treatment of patients with HER2-positive early-stage breast cancer.
Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.
Robert G. Uzzo, MD, MBA, FACS, discusses the evolving yet relevant role of surgery in renal cell carcinoma.
Lewis R. Roberts, MB, ChB, PhD, discusses the past, present, and future of treatment in patients with perihilar and intrahepatic cholangiocarcinoma.  
Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology.
Davendra Sohal, MD, MPH, discusses the SWOG S1505 data and other emerging areas of research in pancreatic cancer.
Edgardo S. Santos, MD, FACP, FCCP, discusses data from the PACIFIC trial and how it has changed the standard of care for stage III non–small cell lung cancer patients whose disease has not progressed following concurrent platinum-based chemoradiation.
Faculty from Duke Cancer Institute provide insight into the exciting breast cancer research being conducted at their institution.
Alberto Chiappori, MD, discusses emerging biomarkers in non–small cell lung cancer and the different ways to test for them.
Atlantic Health System of Morristown New Jersey and Translational Genomics Research Institute of Arizona have opened a center dedicated to phase I clinical trials in cancer and improving access for patients with limited coverage.
David H. Ilson, MD, PhD, discusses the utility of TAS-102 in gastric and GEJ adenocarcinoma as well as other encouraging research in these spaces.
Donald A. Richards, MD, PhD, highlights the key takeaways from the pivotal POLO trial and underscores the importance of genetic testing in metastatic pancreatic cancer.
Sarah Sammons, MD, discussed the MONALEESA-7 and MONARCH 2 studies and how CDK4/6 inhibitors are changing the advanced hormone receptor–positive, HER2-negative breast cancer space.
The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma to include a category 1 recommendation for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell tumor.
The FDA has approved daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Jasmine M. Zain, MD, discusses the phase III ECHELON-2 trial and the ongoing work being done in peripheral T-cell lymphoma and other T-cell lymphomas.
Susan Faye Dent, MD, discussed the importance of cardiac health in patients with breast cancer.
Raja Mudad, MD, FACP, discussed the available EGFR inhibitors and sequencing challenges for patients with EGFR-mutant non-small cell lung cancer.
Carey K. Anders, MD, discussed current approaches in the management of patients with breast cancer that has metastasized to the brain.
Miguel A. Villalona-Calero, MD, discusses the availability of ALK inhibitors for patients with ALK-positive non–small cell lung cancer and the importance of implementing sequencing panels to guide treatment.
Nivolumab monotherapy demonstrated promising activity in a small number of patients with recurrent or metastatic cervical, vaginal, and vulvar cancer.
Two clinical trials evaluating blinatumomab compared with chemotherapy in pediatric patients with acute lymphoblastic leukemia were stopped early due to treatment benefit with the bispecific T-cell engager.
Hossein Borghaei, DO, discusses pivotal and ongoing trials driven by biomarkers in lung cancer.
Jeremy M. Force, DO, discussed current and emerging immunotherapy options and ongoing challenges in metastatic triple-negative breast cancer.
John M. Timmerman, MD, discusses the research being conducted across the spectrum of Hodgkin and non-Hodgkin lymphoma.
Matthew G. Mei, MD, discusses current considerations in the frontline management of advanced-stage Hodgkin lymphoma as well as ongoing investigations with checkpoint inhibitors and cellular-based therapy.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.
Kanwarpal S. Kahlon, MD, discusses current treatment options for patients with aplastic anemia, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura, as well as future research for the field.